Involvement of Fibroblast Growth Factor Receptor Genes in Benign Prostate Hyperplasia in a Korean Population

Table 1

Clinical characteristics of benign prostatic hyperplasia (BPH) patients and control subjects.

	BPH	Control
No. of subjects	233	213
Age (mean ± S.D.)	65.77±9.46	61.89±8.26
Prostate volume (mL)
Total	38.34±21.38
Inner	17.99±18.60
PSA (ng/mL)
Total	4.38±5.24
Free	0.99±1.22
IPSS	17.05±7.66
QoL	3.61±1.34
Uroflowmetry (mL/s)
𝑄max	11.33±5.77
𝑄avg	6.46±3.67
VV (mL)	109.00±148.33
PVR (mL)	57.59±98.68

PSA: prostate-specific antigen; IPSS: international prostate symptom score; QoL: quality of life; 𝑄_max: peak urinary flow rate; 𝑄_avg: average urinary flow rate; VV: voided volume; PVR: postvoid residual urine.